Ascendis Pharma AS (ASND)

Currency in USD
244.59
+1.14(+0.47%)
Closed·
243.50-1.09(-0.45%)
·
Advertisement
Earnings results expected tomorrow
ASND is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
239.56247.98
52 wk Range
175.19282.15
Key Statistics
Prev. Close
244.59
Open
245.9
Day's Range
239.56-247.98
52 wk Range
175.19-282.15
Volume
791.83K
Average Volume (3m)
693.6K
1-Year Change
31.0842%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ASND Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
308.78
Upside
+26.24%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Ascendis Pharma AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

18 Buy
0 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 308.78
(+26.24% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Buy275.00+12.43%256.00Maintain23/07/2026
BofA Securities
Buy306.00+25.11%288.00Maintain14/07/2026
RBC Capital
Buy280.00+14.48%275.00Maintain07/07/2026
Oppenheimer
Buy262.00+7.12%-Maintain15/06/2026
Oppenheimer
Buy262.00+7.12%-Maintain09/06/2026

Ascendis Pharma AS SWOT Analysis


Pipeline Promise
Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development.
Market Dominance
Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients.
Financial Trajectory
Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026.
Analyst Optimism
Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25.
Read full SWOT analysis

Ascendis Pharma AS Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of EUR 0.27 beat forecast by 50%, but revenue of EUR 247M missed estimates by 8.65%, triggering 4.59% stock decline in pre-market.
  • Achieved non-IFRS operating profit of EUR 55M with 22% margin; net profit reached EUR 629M, boosted by EUR 679M deferred tax asset recognition.
  • YORVIPATH and SKYTROFA demonstrated strong demand, supporting market expansion despite revenue shortfall attributed to temporary one-time impacts.
  • Company projects Q2 2026 EPS of EUR 1.14 and full-year FY2026 EPS of EUR 5.62, signaling confidence in continued profitability and growth trajectory.
  • CEO Mikkelsen emphasized commitment to innovation and patient-centric solutions, while management focuses on expanding market access amid competitive pressures.
Last Updated: 07/05/2026, 15:32
Read Full Transcript

Earnings

Latest Release
07/05/2026
EPS / Forecast
0.27 / 0.18
Revenue / Forecast
246.6M / 269.95M
EPS Revisions
Last 90 days

Compare ASND to Peers and Sector

Metrics to compare
ASND
Peers
Sector
Relationship
P/E Ratio
28.2x−5.2x−0.4x
PEG Ratio
0.120.120.00
Price/Book
28.7x4.3x2.6x
Price / LTM Sales
16.2x10.9x3.0x
Upside (Analyst Target)
25.5%38.1%51.9%
Fair Value Upside
Unlock1.9%7.2%Unlock

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
17.92M27.18%4.36B
Other Institutional Investors
8.81M13.36%2.14B
Public Companies & Retail Investors
39.20M59.46%9.54B
Total
65.92M100.00%16.05B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
T. Rowe Price Group, Inc.20.56%13,553,8763,299,691
T. Rowe Price Capital Appreciation Fund, Inc.5.10%3,364,767819,153

People Also Watch

617.68
AGX
+4.22%
88.380
LQDA
+5.40%
3.740
AQST
-1.32%
51.54
FLR
+2.73%
1,275.05
TDG
-0.82%

FAQ

What Is the Ascendis Pharma AS (NASDAQ: ASND) Share Price Today?

The Ascendis Pharma AS stock price today is 244.59 USD.

What Stock Exchange Does Ascendis Pharma AS (ASND) Trade On?

Ascendis Pharma AS is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Ascendis Pharma AS?

The stock symbol (also called a 'ticker') for Ascendis Pharma AS is "ASND."

What Is the Current Ascendis Pharma AS Market Capitalisation?

As of today, Ascendis Pharma AS (NASDAQ: ASND) market cap is 16.12B USD.

What Is Ascendis Pharma AS's (ASND) Earnings Per Share (TTM)?

The Ascendis Pharma AS EPS is currently 8.04 (Trailing Twelve Months).

When Is the Next Ascendis Pharma AS Earnings Date?

Ascendis Pharma AS's next earnings report will be released on 06/08/2026.

Is ASND a Buy or Sell From a Technical Analyst Perspective?

Based on today's Ascendis Pharma AS moving averages and other technical indicators, the daily buy/sell signal for ASND stock is Strong Sell.

How Many Times Has Ascendis Pharma AS Stock Split?

Ascendis Pharma AS has split 0 times. (See the ASND stock split history page for full effective split date and price information.)

How Many Employees Does Ascendis Pharma AS Have?

Ascendis Pharma AS has 1189 employees, based on their latest Companies House report.

What is the current trading status of Ascendis Pharma AS (NASDAQ: ASND)?

As of 05/08/2026, Ascendis Pharma AS (ASND) is trading at a share price of 244.59 USD, with a previous close of 244.59 USD. The stock has fluctuated within a day range of 239.56 USD to 247.98 USD, while its 52-week range spans from 175.19 USD to 282.15 USD.

What Is Ascendis Pharma AS (ASND) Price Target According to Analysts?

The average 12-month price target for Ascendis Pharma AS is 308.78 USD, with a high estimate of 357.99030918 USD and a low estimate of 260.5191509 USD. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.24% Upside potential.

What Is the ASND Premarket Price?

ASND's last pre-market stock price is 243.50 USD. The pre-market share volume is 1,140.00, and the stock has decreased by -1.09, or -0.45%.

What Is the ASND After Hours Price?

ASND's last after hours stock price is 241.18 USD, the stock has decreased by -3.41, or -1.39%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.